958.4000 -1.30 (-0.14%)
NSE Aug 13, 2025 15:31 PM
Volume: 51,830
 

958.40
-0.14%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Alivus Life Sciences.. has an average target of 1317.00 from 1 broker.
More from Alivus Life Sciences Ltd.
Recommended